-
EP3908291
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3908291
| EP3908291 - SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN DTAG SYSTEMS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 08.09.2023 Database last updated on 20.07.2024 | |
| Former | Request for examination was made Status updated on 15.10.2021 | ||
| Former | The international publication has been made Status updated on 18.07.2020 | Most recent event Tooltip | 29.01.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Dana-Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, MA 02215 / US | [2022/27] |
| Former [2021/46] | For all designated states Dana Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, Massachusetts 02215-5450 / US | Inventor(s) | 01 /
GRAY, Nathanael S. 26 Greenview Avenue Boston, Massachusetts 02130 / US | 02 /
FERGUSON, Fleur M. 187 Bookline Avenue Cambridge, Massachusetts 02139 / US | 03 /
NABET, Behnam 8 Kilsyth Terrace, Apt. 34 Boston, Massachusetts 02135 / US | 04 /
BUCKLEY, Dennis L. 240 Sidney Street Cambrdige, Massachusetts 02139 / US | [N/P] |
| Former [2021/46] | 01 /
GRAY, Nathanael S. Boston, Massachusetts 02130 / US | ||
| 02 /
FERGUSON, Fleur M. Cambridge, Massachusetts 02139 / US | |||
| 03 /
NABET, Behnam Boston, Massachusetts 02135 / US | |||
| 04 /
BUCKLEY, Dennis L. Cambrdige, Massachusetts 02139 / US | Representative(s) | Haseltine Lake Kempner LLP Cheapside House 138 Cheapside London EC2V 6BJ / GB | [2021/46] | Application number, filing date | 20737913.2 | 06.01.2020 | [2021/46] | WO2020US12348 | Priority number, date | US201962789230P | 07.01.2019 Original published format: US 201962789230 P | [2021/46] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020146250 | Date: | 16.07.2020 | Language: | EN | [2020/29] | Type: | A1 Application with search report | No.: | EP3908291 | Date: | 17.11.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.07.2020 takes the place of the publication of the European patent application. | [2021/46] | Search report(s) | International search report - published on: | US | 16.07.2020 | (Supplementary) European search report - dispatched on: | EP | 08.12.2022 | Classification | IPC: | A61K35/17, C12N9/22, C07K14/82, A61K47/55, A61K38/00, A61P35/00, C12N9/10, C12N9/90, C07K14/725 | [2022/40] | CPC: |
C12N9/104 (EP);
C07D417/14 (US);
A61K35/17 (EP,US);
A61K47/55 (EP);
A61P35/00 (EP);
C07K14/7051 (EP);
C07K14/82 (US);
C12N15/8509 (US);
C12N5/0636 (EP,US);
C12N9/90 (EP);
C12Y203/02 (EP);
C12Y502/01008 (EP);
A01K2227/105 (US);
A01K2267/0331 (US);
A61K38/00 (EP);
C07K2319/00 (EP);
C07K2319/03 (EP);
C07K2319/60 (EP);
|
| Former IPC [2021/46] | A61K35/17, C12N9/22, C07K14/82 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/46] | Title | German: | NIEDERMOLEKULARE DEGRADER VON FKBP12 ÜBER REKRUTIERUNG DER VON-HIPPEL-LINDAU-E3-UBIQUITIN-LIGASE (VHL) UND VERWENDUNG IN DTAG-SYSTEMEN | [2021/46] | English: | SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN DTAG SYSTEMS | [2021/46] | French: | AGENTS DE DÉGRADATION DE PETITES MOLÉCULES DE FKBP12 PAR RECRUTEMENT DE L'UBIQUITINE LIGASE E3 DE VON HIPPEL-LINDAU (VHL), ET UTILISATIONS DANS DES SYSTÈMES DTAG | [2021/46] | Entry into regional phase | 19.06.2021 | National basic fee paid | 19.06.2021 | Search fee paid | 19.06.2021 | Designation fee(s) paid | 19.06.2021 | Examination fee paid | Examination procedure | 19.06.2021 | Examination requested [2021/46] | 06.07.2023 | Amendment by applicant (claims and/or description) | 11.09.2023 | Despatch of a communication from the examining division (Time limit: M04) | 10.01.2024 | Reply to a communication from the examining division | Fees paid | Renewal fee | 27.01.2022 | Renewal fee patent year 03 | 27.01.2023 | Renewal fee patent year 04 | 29.01.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [D]WO2017024318 (DANA FARBER CANCER INST INC [US]) [D] * page 374 *; | WO2017024317 [ ] (DANA FARBER CANCER INST INC [US]) [ ] * abstract * * claims 14,54 * * page 39 - page 53 * * page 33, line 21 * * page 142; compounds dFKBP-8-o'' *; | WO2018148443 [ ] (DANA FARBER CANCER INST INC [US]); | WO2018148440 [ ] (DANA FARBER CANCER INST INC [US]) [ ] * abstract *; | [XI] - Buckley D, "TUNABLE ENDOGENOUS PROTEIN DEGRADATION WITH HETEROBIFUNCTIONAL COMPOUNDS - WO2018/148443 A1", REAXYS, Elsevier, (20180816), Database accession no. XRN = 33551764, XP055952184 [X] 1,7,8,15 * abstract * [I] 2-6,16 | [XDI] - Bradner James ;, "Using heterobifunctional compounds for targeted CAR protein degradation to attenuate adoptive immunotherapy associated adverse inflammation - WO 2017024318 A1", CAPLUS, (20170101), Database accession no. 2017:229794, URL: ACS, XP055952197 [XD] 1,7,8,15 * abstract * [I] 2-6,16 | [XDI] - Bradner James ;, "Using heterobifunctional compounds for targeted CAR protein degradation to attenuate adoptive immunotherapy associated adverse inflammation - WO 2017024318 A1", CAPLUS, (20170101), Database accession no. 2017:229794, URL: ACS, XP055952509 [XD] 1,7,8,15 * abstract * [I] 2-6,16 | [XI] - Bradner James, "Methods to induce targeted protein degradation through bifunctional molecules - WO 2017024317 A2", CAPLUS, (20170101), Database accession no. 2017:229795, URL: ACS, XP055952510 [X] 1,7,8,15 * abstract * [I] 2-6,16 | [XI] - PHILIPP OTTIS ET AL, "Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation", ACS CHEMICAL BIOLOGY, (20170905), vol. 12, no. 10, doi:10.1021/acschembio.7b00485, ISSN 1554-8929, pages 2570 - 2578, XP055618965 [X] 1,7,8,15 * figure 2 * * abstract * [I] 2-6,16 DOI: http://dx.doi.org/10.1021/acschembio.7b00485 | [XAI] - Bradner James, "Regulating CAR-cells against inflammatory side effects by targeted CAR protein degradation through the use of ubiquitin ligase binding heterobifunctional compounds - WO 2018148440 A1", CAPLUS, (20180101), Database accession no. 2018:1504369, URL: ACS, XP055952511 [X] 1,7,8,15 * abstract * [A] 5,6 [I] 2-4,16 | International search | [YA]WO2017024317 (DANA FARBER CANCER INST INC [US]) [Y] 26 * ; page 5, lines 5-26; page 32, lines 5-12 * * ; entire document *[A] 1-6, 7/1-6, 8-12, 13/11-12,14/11-12, 15/14/11-12, 16/15/14/11-12, 17, 18/11-12, 26; | [Y]WO2017180417 (UNIV MICHIGAN REGENTS [US]) [Y] 1, 9-10 * ; paragraphs [0041]-[0043], [0491], [0499] *; | [Y] - NABET, B et al., "The dTAG system for immediate and target-specific protein degradation", Nature Chemical Biology, (20180500), vol. 14, no. 5, pages 431 - 441, XP036478801 [Y] 1-6, 7/1-6, 8-12, 13/11-12, 14/11-12, 15/14/11-12, 16/15/14/11-12, 17, 18/11-12, 26 * ; page 2, graphic abstract; figure 1; page 5, second, third, and fourth paragraphs; page 9, second paragraph * DOI: http://dx.doi.org/10.1038/s41589-018-0021-8 | [Y] - MANIACI, C et al., "Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation", Nature Communications, (20171010), pages 1 - 14, XP055476041 [Y] 1-6, 7/1-6, 8, 11-12, 13/11-12, 14/11-12, 15/14/11-12, 16/15/14/11-12, 17, 18/11-12, 26 * ; abstract; page 3, figure 1; page 8, first column, last paragraph * DOI: http://dx.doi.org/10.1038/s41467-017-00954-1 |